Pirfenidone for IPF: Pro/con debate; the 'con' viewpoint

Thorax

Volumn 68, Issue 7, 2013, Pages 605-608

  Raghu, Ganesh ^a   Thickett, David R ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FIBROBLAST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC PREDISPOSITION; HUMAN; LIVER DYSFUNCTION; LUNG FUNCTION; MACROPHAGE; MOLECULAR DYNAMICS; MYOFIBROBLAST; NEUTROPHIL COUNT; NONHUMAN; OXYGEN DESATURATION; PATHOGENESIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; VITAL CAPACITY; WOUND HEALING;

IDIOPATHIC PULMONARY FIBROSIS;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PRESCRIPTION DRUGS; PYRIDONES;

EID: 84879399953     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-201269     Document Type: Review

References (24)

1. Jenkins G. Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax 2013 (in press).
2. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159(4 Pt 1):1061-9. (Pubitemid 29202536)
3. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011;38:1461-7.
4. Cool CD, Groshong SD, Rai PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006;174:654-8. (Pubitemid 44395332)
5. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-61.
6. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226-32.
7. Gunther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000;83:853-60. (Pubitemid 30411683)
8. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004;170:242-51. (Pubitemid 38971408)
9. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011;38:1461-7.
10. Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008;82:210-7.
11. Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006;21:145-51. (Pubitemid 44637968)
12. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
13. Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003;16:207-14. (Pubitemid 36798118)
14. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9.
15. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7. (Pubitemid 40616955)
16. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
17. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. (Pubitemid 47503070)
18. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
19. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
20. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7. (Pubitemid 37088594)
21. fibrosis NpbPftip. Idiopathic pulmonary fibrosispirfenidone: Evidence Review Group Report. 2012.
22. Parfrey HLC, Gibbons MA, Maher T, et al. Clinical studies in interstitial lung disease: S98 early clinical experience with pirfenidone for idiopathic pulmonary fibrosis (IPF) in the UK: interim results from a UK cohort. Thorax 2012;67(suppl 2):A48-A49.
23. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013;68:155-62.
24. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35:496-504.